Displaying drugs 10176 - 10200 of 12589 in total
NV1020
NV1020, a genetically engineered herpes simplex virus, is a novel anticancer therapeutic.
Investigational
LErafAON
NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation or chemotherapy. Phase I/II trials commenced in March 2001 and were ongoing as of June 2003.
Investigational
Matched Description: … Phase I/II trials commenced in March 2001 and were ongoing as of June 2003. ... liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of …
SP1049C
SP1049C is a novel anthracycline chemotherapeutic agent containing doxorubicin and two nonionic pluronic block copolymers. It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review. Preliminary data, in its first clinically tested indication,...
Investigational
Matched Description: … [A260416] It is designed to overcome drug resistance in a number of cancers. ... clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of …
IGN311
IGN311 is a humanized monoclonal antibody (mab) against the Lewis Y carbohydrate antigen, a blood-group-related oligosaccharide.
Investigational
M40403
M40403 is a low molecular weight, synthetic manganese containing superoxide dismutase mimetic (SODm) that selectively removes superoxide anion.
Investigational
SR 121463
SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Investigational
Matched Description: … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion ... of anti-diuretic hormone (SIADH). ... SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 ( …
Gantenerumab
Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological hallmarks including extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs). As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and cause neurodegeneration, large...
Investigational
Matched Description: … As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and ... Alzheimer's disease (AD) is the most common cause of dementia in elderly patients, with classical histopathological ... Despite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation …
Atipamezole
Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs. It has also been undergone research as a potential anti-Parkinsonian drug for humans.
Investigational
Vet approved
Matched Description: … Atipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of …
DG051
DG051 is a novel small-molecule inhibitor of leukotriene A4 hydrolase (LTA4H), the protein made by one of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4...
Investigational
Matched Description: … ), an end product of the leukotriene pathway and a potent promoter of inflammation. ... of the genes in the leukotriene pathway that has been shown to link to risk of heart attack. ... DG051 is designed to decrease risk of heart attack by decreasing the production of leukotriene B4 (LTB4 …
Iscalimab
Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome).
Investigational
Matched Description: … Doses of CFZ533 in Two Distinct Populations of Patients With Sjögren's Syndrome). ... Iscalimab is under investigation in clinical trial NCT03905525 (Study of Safety and Efficacy of Multiple …
ABT-737
An inhibitor of members of the Bcl‑2 family of apoptosis regulators.
Investigational
Matched Description: … An inhibitor of members of the Bcl‑2 family of apoptosis regulators.[A252977] …
Ty800
Ty800 is a vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of typhoid fever. The Ty800 vaccine was developed using genetic techniques to delete specific genes known to be essential to the virulence of S. typhi. It is being developed by AVANT Immunotherapeutics, Inc.
Investigational
Matched Description: … vaccine designed to offer rapid, oral, single-dose protection against Salmonella typhi, the cause of ... developed using genetic techniques to delete specific genes known to be essential to the virulence of …
AC3056
AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression originally developed by Aventis Pharmaceuticals. It as since been acquired by Amylin Pharmaceuticals and has completed phase I trials.
Investigational
Matched Description: … AC3056 is a non-peptide antioxidant that acts as an inhibitor of vascular cell adhesion molecule expression …
XL281
XL281 is a novel anticancer compound designed to potently inhibit the RAS/RAF/MEK/ERK signaling pathway. Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer. XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which...
Investigational
Matched Description: … in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers. ... Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell ... XL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated …
Fencamfamin
Fencamfamin (Glucoenergan, Reactivan) is a stimulant which was developed in the 1960s as an appetite suppressant, but was later withdrawn for this application due to problems with dependence and abuse. It is around half the potency of dexamphetamine, and is prescribed at a dose of 10-60mg, although abusers of the...
Experimental
Illicit
Withdrawn
Matched Description: … It is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers ... of the drug tend to rapidly develop tolerance and escalate their dose. ... Fencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. …
AZD7442
AZD7442 is a combination of SARS-CoV-2 antibodies (AZD8895 + AZD1061) currently undergoing phase I clinical trials for the prevention and treatment of COVID-19. It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that...
Investigational
Matched Description: … against COVID-19 - a significantly longer window of efficacy than that of other vaccines. ... [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection ... trials for the prevention and treatment of COVID-19. …
Didesmethylrocaglamide
Didesmethylrocaglamide is a naturally-occurring derivative of rocaglamide and belongs to a class of anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus Aglaia. While traditionally used for their insecticidal benefits, this class of compounds is now being studied for use as chemotherapeutic agents in the treatment of...
Experimental
Matched Description: … Didesmethylrocaglamide is a naturally-occurring derivative of [rocaglamide] and belongs to a class of ... [A186802,A186763,A186781,A186784] Of the known derivatives of rocaglamide, didesmethylrocaglamide appears ... anti-cancer phytochemicals referred to as "rocaglamides" derived from plants of the genus _Aglaia_. …
Biropepimut-S
Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity).
Investigational
Matched Description: … (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity ... Biropepimut-S is under investigation in clinical trial NCT02873819 (Safety and Efficacy Study of GL-0817 …
TTP889
TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic pathway of the blood coagulation system. TTP889 has proven...
Investigational
Matched Description: … TTP889 is the only known selective small molecule inhibitor of Factor IX, a key enzyme of the intrinsic ... pathway of the blood coagulation system. ... as an anticoagulant for the treatment of thromboembolic disorders. …
ND7001
ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid. Known drug targets of ND7001 including phosphodiesterase 2A, cGMP-stimulated and cGMP-dependent 3',5'-cyclic phosphodiesterase. It is a new type of antidepressant drug with anxiolytic activity. It is the first representative of a new...
Investigational
Matched Description: … It is the first representative of a new generation of psycho-active compounds potentially devoid of several ... It is a new type of antidepressant drug with anxiolytic activity. ... ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. …
XEN-2174
XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's Great Barrier Reef. XEN-2174 represents a new class of molecules, called the chi conopeptides that selectively inhibit the Norepinephrine Transporter (NET). NET is the primary mechanism regulating the biological effects of...
Investigational
Matched Description: … In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation ... of inhibitory pathways preventing pain signals from reaching the brain. ... XEN-2174 is a synthetic drug modeled on a peptide from the venom of a cone shell found on Australia's …
Rozrolimupab
Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN).
Investigational
Matched Description: … Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN). ... Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies ... to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic …
CX501
Cx501 is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus. It is developed by Cellerix and is in phase I of clinical trials.
Investigational
Matched Description: … the joints, fusion of fingers and toes, contraction of the mouth membranes and narrowing of the oesophagus ... It is developed by Cellerix and is in phase I of clinical trials. ... is used to treat epidermolysis bullosa (EB), a rare genetic condition which can lead to contraction of …
Dectrekumab
Dectrekumab is under investigation in clinical trial NCT00987545 (Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence).
Investigational
Matched Description: … of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence). ... Dectrekumab is under investigation in clinical trial NCT00987545 (Efficacy 2 Part Study of Identification …
Cilansetron
Cilansetron is a 5HT-3 antagonist made by Solvay Pharmaceuticals that is currently under trial phase in the EU and US.
Investigational
Displaying drugs 10176 - 10200 of 12589 in total